The drug, Journavx, or suzetrigine, was approved to treat moderate to severe acute ... pain after their suzetrigine doses.

Medical students often make key mistakes during clinical rotations, such as being too focused on technical tasks. Most ...

The United States Food and Drug Administration (FDA) has approved a new non-opioid prescription medication, Journavx ...

The drug is for moderate to severe acute pain. The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe ...

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid ...

NONPF Educator's Forum, April 2011 Acute Pain: Assessment and Treatment If ... Articles, April 2010 Electronic Medical Records: 18 Ways to Reduce Legal Risks If you use -- or are considering ...

The Regional Anesthesia and Acute Pain Medicine (RAAPM) fellowship program consists of twelve months of post-graduate training after successful completion of an accredited residency program in ...

The new drug “offers a safer option for managing moderate-to-severe acute pain, reducing reliance on opioids,” Dr. Jianguo Cheng, a professor of anesthesiology and medical director of the ...

On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...